Glass House (GLAS) Q2 2026 earnings review
Record Production and a Massive Strategic Pivot, But Margins Lag
Glass House has fundamentally transformed its business model. Effective June 12, the company deconsolidated its retail operations to convert its cultivation licenses to medical, applying for DEA registration to capitalize on Schedule III rescheduling. Operationally, the company is Reversing the production collapse seen in late 2025, hitting a record 245,746 pounds of biomass. However, the volume rebound came at a cost: a higher proportion of 'trim' in the mix and elevated production expenses drove gross margins down to 34% (from 55% a year ago). While revenue recovered sequentially, profitability metrics remain a shadow of their Q2 2025 peaks.
🐂 Bull Case
By shedding retail and registering with the DEA, Glass House is positioning itself as a first-mover for legal interstate and international medical cannabis export under Schedule III.
Biomass production hit an all-time high of 246k pounds, proving the company has successfully resolved the labor constraints that crippled output in late 2025.
🐻 Bear Case
Despite record volume and higher pricing ($211/lb), gross margin collapsed from 55% in Q2 2025 to 34% today, driven by an unfavorable mix shift toward lower-value trim.
Operating cash flow was barely positive at $0.2M, compared to $17.7M in the same quarter last year, highlighting the cash drain of the current cost structure.
⚖️ Verdict: ⚪
Neutral. The strategic pivot to DEA-licensed medical wholesale is a bold, high-upside move, and production has successfully normalized. However, poor product mix (trim) and sticky production costs are severely suppressing the bottom line.
Key Themes
The Schedule III Pivot (Macro)
Glass House executed a drastic corporate restructuring to capitalize on the DEA's rescheduling of medical cannabis. By deconsolidating its retail arm (GHR) and registering its cultivation and processing licenses with the DEA, management believes they are fully compliant to engage in interstate and international medical cannabis commerce. This isolates Glass House as a pure-play, federally registered wholesale medical supplier.
Biomass Production Fully Reversing 2025 Slump
Production is Reversing its prior downtrend. Output hit 245,746 pounds this quarter, vastly outperforming the labor-constrained lows of Q3 2025 (123k lbs) and even beating Q2 2025's strong benchmark (230k lbs). With Greenhouse Two coming online, scale is firmly back in management's favor.
Pricing Power in California
Despite the massive influx of their own supply, California wholesale pricing remains resilient. The Average Selling Price (ASP) hit $211 per pound, Accelerating from $171 in Q1 2026 and $206 a year ago. This suggests the broader California supply glut continues to rationalize.
Product Mix Shift Destroys Margins
The positive narrative of record production and rising ASP is directly contradicted by plunging margins. Consolidated gross margin dropped to 34% (down from 55% YoY). Management explicitly blamed a 'higher proportion of trim within the production mix.' Pumping out record volume means little if the yield is heavily weighted toward low-margin byproducts rather than premium flower.
Cost of Production Remains Stubbornly High
Cost per equivalent dry pound was $122. While this is an improvement from the disastrous $175 in Q1 2026, it is still Decelerating significantly compared to the $91 achieved in Q2 2025. Management maintains a $95 long-term target, but achieving it requires wringing out inefficiencies that have plagued operations for the past twelve months.
Financial Clean-Up & Warrant Acceleration
The company aggressively cleaned up its capital structure, redeeming 30.6M SPAC warrants and accelerating Series B, C, and D warrants. This eliminates significant derivative overhangs and simplifies the equity story ahead of the planned NYSE uplisting.
Other KPIs
Decelerating sharply YoY. While it reversed the negative $11.8M burn from Q1, generating just $200k on $47M in revenue compares poorly to the $17.7M generated in Q2 2025. Working capital changes, particularly a $6.5M increase in payables, masked otherwise weak cash generation.
Stable. Up 14% sequentially but down 4% YoY. With retail now deconsolidated, CPG and Biomass are the only remaining consolidated revenue streams, placing heightened pressure on CPG to prove it can grow without relying entirely on owned-retail shelf space.
Guidance
Accelerating. Reiterated target implies a ~50% YoY volume increase versus FY 2025 (~666k lbs). Reaching a 1.1M lb run rate by year-end depends heavily on the full contribution of Greenhouse Two in the second half of the year.
Management claims this remains 'achievable', but bridging the gap from the current $122/lb requires significant execution. It relies on the scale efficiencies of Greenhouse Two and avoiding further labor or regulatory disruptions.
Key Questions
Trim vs. Flower Mix Duration
You cited a 'higher proportion of trim' as a primary margin drag this quarter. Is this a permanent feature of scaling Greenhouse Two, or a temporary agricultural anomaly that will normalize in H2?
Path to Interstate Commerce
With the DEA applications submitted and retail deconsolidated, what specific federal or state regulatory milestones must be cleared before the first legal interstate or international shipment actually leaves the facility?
Cost Target Bridge
Cost per pound improved to $122 but remains well above the $91 achieved a year ago. Walk us through the exact mechanical steps required to drive this down to your $95 target in the coming quarters.